Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen ...
Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) and keeping the price target at $46.00. Discover outperforming stocks and ...
In a report released today, Serge Belanger from Needham maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report), with a price target of $38.00. Discover outperforming stocks ...
WALTHAM, Mass., January 08, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback